Pain – Opioids

  • Fentanyl Patch 2017 report

    Fentanyl Patch 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 26 Pages The 5 Key Questions Addressed by this...

  • Hysingla ER 2017 report

    Hysingla ER 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 26 Pages The 5 Key Questions Addressed by this...

  • Ionsys 2017 report

    Ionsys 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 32 Pages The 5 Key Questions Addressed by this Report:...

  • Lazanda 2017 report

    Lazanda 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Levorphanol 2017 report

    Levorphanol 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Morphabond ER 2017 report

    Morphabond ER 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 26 Pages The 5 Key Questions Addressed by this...

  • Nucynta 2017 report

    Nucynta 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 30 Pages The 5 Key Questions Addressed by this Report:...

  • Oxaydo 2017 report

    Oxaydo 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • OxyContin 2017 report

    OxyContin 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 26 Pages The 5 Key Questions Addressed by this Report:...

  • Primlev 2017 report

    Primlev 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 28 Pages The 5 Key Questions Addressed by this Report:...

  • Subsys 2017 report

    Subsys 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 32 Pages The 5 Key Questions Addressed by this Report:...

  • Xtampza ER 2017 report

    Xtampza ER 2017 U.S. PROMOTIONAL AUDIT REPORT Published July 2018 • 26 Pages The 5 Key Questions Addressed by this...